Loading stock data…
1,816pGBX+63.00p (+3.59%)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
GSK plc in the Healthcare sector is trading at 1,816p with a market capitalization of $72.8B. Wall Street consensus targets 2,173p (21 analysts), implying a +19.7% move over the next 12 months. The stock is currently 20% below its 52-week high of 2,282p, remaining 6.9% below its 200-day moving average. Risk note: MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (GBP) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | £7.99B↓ | £8.55B↓ | £8.62B↑ | £7.63B↓ | £8.41B |
| Gross Profit | £5.82B↓ | £6.29B↑ | £5.96B↑ | £5.75B↓ | £6.14B |
| Operating Income | £2.02B↓ | £2.59B↑ | £1.51B↓ | £2.29B↑ | £481.00M |
| Net Income | £1.44B↓ | £2.01B↑ | £636.00M↓ | £1.74B↑ | £435.00M |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It oper...